Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trilaciclib plus gemcitabine/carboplatin vs placebo in metastatic TNBC
CTR20211653Phase 3Terminated
- Sponsor
- G1 Therapeutics, Inc.
- Start
- Sep 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of trilaciclib in triple-negative breast cancer (TNBC), sponsored by G1 Therapeutics, Inc.. Started Sep 2021; status: terminated.
02
Drugs
trilaciclib
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on CTR20211653.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20211653.